Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Dans le cadre du traitement du cancer du pancréas, cet article passe en revue les nouvelles stratégies d'immunothérapie en cours d'étude pour conférer aux lymphocytes T une spécificité antigénique, contrer les éléments immunosuppresseurs du microenvironnement tumoral et améliorer la fonction effectrice des lymphocytes T
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumor inception to subvert adaptive T cell immunity. Single-agent immune modulators have thus far proven clinically ineffective, and multi-modal therapies targeting mechanisms of immunotherapy resistance are likely needed. Here, we review novel immunotherapy strategies currently under investigation to (1) confer antigen specificity, (2) enhance T cell effector function, and (3) neutralize immunosuppressive elements within the tumor microenvironment that may be rationally combined to untangle the web of immune resistance in PDA and other tumors.